Prostate

he following list provides a brief description of prostate cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.

Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.

Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.


CORE (TROG 16.03)

Registered Title A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases.
 Purpose The CORE study aims to understand whether there is a benefit in adding a type of radiotherapy called Stereotactic Body Radiation Therapy (SBRT) to the standard treatment in people with breast, prostate, or non-small cell lung cancer (NSCLC) which has spread to 3 or less areas of the body (known as oligometastatic disease).
 Lay Summary  Assessing the benefit of targeted radiotherapy added to standard of care in the management of isolated metastases outside the brain.
 WA Trial Sites

SCGH - Radiation Oncology (08) 6383 3204

 Links  US National Library of Medicine

Acknowledgements:US National Library of Medicine

 

TheraP

Registered Title A randomised phase 2 trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer
Purpose The primary purpose of this trial is to evaluate the efficacy and safety of a new radionuclide therapy (177Lu-PSMA617) for advanced prostate cancer, in comparison to the standard care, cabazitaxel.

177Lu-PSMA617 is a radioactive molecule that specifically attaches to cells with high amounts of PSMA on the surface of the cells. This allows the radioactivity to be delivered mainly to the prostate cancer cells wherever they have spread, while sparing most normal tissues.

Lay Summary

Who is it for?

You may be eligible to participate in this trial if you have been diagnosed with metastatic castration resistant prostate cancer for which you have previously received docetaxel.

Study details
All patients enrolled into this trial will be randomly allocated (by chance) to receive either 177Lu-PSMA617 or the standard care cabazitaxel chemotherapy. Patients in the 177Lu-PSMA617 arm will receive up to six six-weekly doses of 177Lu-PSMA617. Patients in the cabazitaxel arm will receive up to ten three-weekly doses of cabazitaxel. Treatment in both arms will continue until your cancer progresses, you have unmanageable side effects or until the maximum number of treatments has been reached.

All patients will complete scans and questionnaires as part of this trial, up to every 3 weeks, to assess the impact of the treatment on your cancer, on your pain levels and your quality of life.

It is hoped that this trial will provide further information on the risks and benefits of 177Lu-PSMA617 treatment compared with cabazitaxel in men with advanced prostate cancer.

WA Trial Sites

FSH - Cancer Centre Clinical Trials Unit (08) 615 26530

Links  Australian New Zealand Clinical Trials Registry

Acknowledgments: Australian New Zealand Clinical Trials Registry

 

TRITON2

Registered Title

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency

Purpose

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.

Lay Summary

N/A

WA Trial Sites

St John of God - Subiaco (08) 6465 9204

Links

US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

TRITON3

Registered Title

TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency

Purpose

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Lay Summary

N/A

WA Trial Sites

St John of God - Subiaco (08) 6465 9204

Links

US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

PROfound

Registered Title
 A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparzaâ„¢) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)
 Purpose  The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.
 Lay Summary
N/A
 WA Trial Sites

 SCGH - Medical Oncology (08) 6383 3000

 Links US National Library of Medicine 

Acknowledgements: US National Library of Medicine

 

 

[Return to List of Clinical Trials]